Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology, Guwahati, 781039, Assam, India.
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117600, Singapore.
Phytomedicine. 2022 Oct;105:154369. doi: 10.1016/j.phymed.2022.154369. Epub 2022 Aug 1.
Regardless of major advances in diagnosis, prevention and treatment strategies, cancer is still a foreboding cause due to factors like chemoresistance, radioresistance, adverse side effects and cancer recurrence. Therefore, continuous development of unconventional approaches is a prerequisite to overcome foregoing glitches. Natural products have found their way into treatment of serious health conditions, including cancer since ancient times. The compound oroxylin A (OA) is one among those with enormous potential against different malignancies. It is a flavonoid obtained from the several plants such as Oroxylum indicum, Scutellaria baicalensis and S. lateriflora, Anchietea pyrifolia, and Aster himalaicus.
The main purpose of this study is to comprehensively elucidate the anticancerous effects of OA against various malignancies and unravel their chemosensitization and radiosensitization potential. Pharmacokinetic and pharmacodynamic studies of OA have also been investigated.
The literature on antineoplastic effects of OA was searched in PubMed and Scopus, including in vitro and in vivo studies and is summarized based on a systematic review protocol prepared according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The term "oroxylin A" was used in combination with "cancer" and all the title, abstracts and keywords appeared were considered.
In Scopus, a total of 157 articles appeared out of which 103 articles that did not meet the eligibility criteria were eliminated and 54 were critically evaluated. In PubMed, from the 85 results obtained, 26 articles were eliminated and 59 were included in the preparation of this review. Mounting number of studies have illustrated the anticancer effects of OA, and its mechanism of action.
OA is a promising natural flavonoid possessing wide range of pleiotropic properties and is a potential anticancer agent. It has a great potential in the treatment of multiple cancers including brain, breast, cervical, colon, esophageal, gall bladder, gastric, hematological, liver, lung, oral, ovarian, pancreatic and skin. However, lack of pharmacokinetic studies, toxicity assessments, and dose standardization studies and adverse effects limit the optimization of this compound as a therapeutic agent.
尽管在诊断、预防和治疗策略方面取得了重大进展，但由于化疗耐药、放疗耐药、不良反应和癌症复发等因素，癌症仍然是一个令人担忧的原因。因此，不断开发非常规方法是克服上述障碍的前提。自古以来，天然产物就被用于治疗包括癌症在内的严重健康问题。化合物白杨素 A（OA）是对抗多种恶性肿瘤具有巨大潜力的化合物之一。它是从几种植物中获得的黄酮类化合物，如黄桐、黄芩和野黄芩、鸡脚草和喜马拉雅紫菀。
本研究的主要目的是全面阐明 OA 对各种恶性肿瘤的抗癌作用，并揭示其化学增敏和放射增敏潜力。还研究了 OA 的药代动力学和药效学。
在 PubMed 和 Scopus 中搜索关于 OA 的抗肿瘤作用的文献，包括体外和体内研究，并根据系统评价协议进行综述，该协议根据系统评价和荟萃分析报告的首选项目准备。使用“白杨素 A”一词与“癌症”结合，并且考虑了所有标题、摘要和关键字。
在 Scopus 中，共出现 157 篇文章，其中 103 篇不符合入选标准的文章被淘汰，54 篇文章进行了批判性评估。在 PubMed 中，从获得的 85 个结果中，淘汰了 26 个，有 59 个被纳入本综述的编写。越来越多的研究表明 OA 具有抗癌作用及其作用机制。
OA 是一种有前途的天然类黄酮，具有广泛的多效性，是一种有潜力的抗癌药物。它在治疗多种癌症方面具有很大的潜力，包括脑、乳腺、宫颈、结肠、食管、胆囊、胃、血液、肝、肺、口腔、卵巢、胰腺和皮肤。然而，缺乏药代动力学研究、毒性评估、剂量标准化研究和不良反应限制了该化合物作为治疗剂的优化。
